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Abstract
Objective. Up to 90% of patients with advanced
cancer experience intractable pain. For these
patients, oral analgesics are the mainstay of
therapy, often augmented with intrathecal drug
delivery. Neurosurgical ablative procedures have
become less commonly used, though their efficacy
has been well-established. Unfortunately, little is
known about the safety of ablation in the context of
previous neuromodulation. Therefore, the aim of
this study is to present the results from a case
series in which patients were treated successfully
with a combination of intrathecal neuromodulation
and neurosurgical ablation.
Design. Retrospective case series and literature
review.
Setting. Three institutions with active cancer pain
management programs in the United States.
Methods. All patients who underwent both
neuroablative and neuromodulatory procedures for
cancer pain were surveyed using the visual analog
scale prior to the first procedure, before and after a
second procedure, and at long-term follow-up.
Based on initial and subsequent presentation,
patients underwent intrathecal morphine pump
placement, cordotomy, or midline myelotomy.
Results. Five patients (2 male, 3 female) with medi-
cally intractable pain (initial VAS = 10) were included
in the series. Four subjects were initially treated with
intrathecal analgesic neuromodulation, and 1 with
midline myelotomy. Each patient experienced
recurrence of pain (VAS ≥ 9) following the initial
procedure, and was therefore treated with another
modality (intrathecal, N = 1; midline myelotomy,
N = 1; percutaneous radiofrequency cordotomy,
N = 3), with significant long-term benefit (VAS 1–7).
Conclusion. In cancer patients with medically
intractable pain, intrathecal neuromodulation and
neurosurgical ablation together may allow for more
effective control of cancer pain.
Key Words. Cancer Pain; Intrathecal; Ablation;
Surgery
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Introduction
Many cancer patients suffer from intractable pain, with
an increasing incidence as the disease progresses [1].
An estimated 60% to 90% of patients experience sig-
nificant pain in the terminal stages [2–6]. With the
success of intrathecal (IT) opioids and other
neuromodulatory therapies, such as spinal cord stimu-
lation, ablative procedures are now less commonly
used [7]. Ablative therapies for cancer include cor-
dotomy, myelotomy, sympathectomy, peripheral neurec-
tomy, dorsal rhizotomy and ganglionectomy, dorsal root
entry zone lesioning, and others [7,8]. Among these, two
of the most commonly indicated procedures are the cor-
dotomy and myelotomy. Cordotomy was first described
in 1912 by Spiller and Martin as an open procedure [9],
and has evolved into an image-guided percuta-
neous procedure with low morbidity [10–12]. Indicated
for patients with refractory unilateral pain, this technique
introduces a lesion into in the rostral cervical spinal cord
for interruption of ascending spinothalamic tract fibers.
In addition to its safety profile, it is also associated
with short hospitalizations and relatively low costs [13].
Similarly, the midline myelotomy has low morbidity,
and is performed either percutaneously or via an open
laminectomy. It is indicated for midline abdominal or
pelvic pain, typically in the setting of visceral malig-
nancy, and results in interruption of dorsal crossing fibers
of the spinothalamic tract [13,14]. Intrathecal therapy,
first introduced in humans in 1979 [15], has therapy has
proven to be a highly effective treatment option for
patients with opioid-responsive pain that require increas-
ing doses or experience intolerable side effects. IT medi-
cation delivery allows 100-fold greater potency than
orally administered medications, and has a broader
therapeutic range due to lowered potential for systemic
side effects [16,17]. In part due to these reasons,
the use of neuroablation has declined in recent
years [18].
Despite the multiple available treatments for pain
control and the existence of well-established guide-
lines [19], undertreatment of cancer pain remains in
the neighborhood of 50% [20]. In addition, a subset of
patients continue to experience refractory pain after
optimization of oral and intrathecal medications
[21], but guidance in choosing further therapies is
lacking. Although IT opioids and neurosurgical ablation
have been well-described individually, with published
series exploring the outcomes of patients treated
with either neuromodulation [22–25] or surgical ablation
[10,26–29], little is known about the potential appli-
cation of both modalities together in individual patients.
but not both. In this case series, we report 5 patients
with medically intractable cancer pain in whom a
second interventional modality proved successful after
the other interventional modality failed. The series
illustrates the potential efficacy of a multi-modal
interventional approach to cancer pain, performed
sequentially, when other medical therapies have
failed.
Materials and Methods
Patient Selection
All data collection was performed with the approval of,
and in accordance with Internal Review Board (IRB) pro-
tocols at each of the participating institutions. All patients
without exception who underwent both neuroablation and
intrathecal drug delivery for cancer pain between January
2011 and December 2013 were selected for this retro-
spective review. A total of five patients were identified from
the three participating institutions. For opioid-responsive
patients, IT therapy was typically selected as the initial
treatment. In response to a return of pain, or the extension
of pain to a new area, patients underwent a second,
adjunctive procedure. For those with unilateral pain, PRFC
was chosen, and those with bilateral or midline pain
underwent MM. Visual analog scale (VAS) scores were
assessed pre-operatively, immediately post-operatively,
and at long-term follow-up. Cases were also assessed for
any complications.
Neuromodulation and Neurosurgical Techniques
IT catheter and subcutaneous pump placement, MM, and
PRFC were all performed using standard surgical tech-
niques, which have been previously described [30–33].
Briefly, intrathecal pump placement involves percutaneous
introduction of a catheter in a procedure similar to lumbar
puncture. The catheter is tunneled to the abdomen where
it is attached to a subcutaneous medication reservoir.
Level of catheter placement is typically several segments
above the level of pain to ensure adequate coverage [31].
Cordotomy is also frequently performed percutaneously,
with needle localization at C1-2 level under fluoroscopic or
CT-guidance. The needle trajectory is towards the antero-
lateral quadrant of the spinal cord on the contralateral
side, at least several segments above the level of pain
where spinothalamic tract fibers have crossed [34].
Midline myelotomy may be performed open or percutane-
ously, and is designed to interrupt of dorsal crossing fibers
of the spinothalamic tract by making a small incision. It is
typically performed several levels above the level of pain to
ensure coverage [14,32].
Results
In our series, there were 2 male patients and 3 female
patients. Subjects ranged in age from 16 to 72 years, and
were diagnosed with commonly occurring cancers (renal
carcinoma, N = 1; non-small cell lung cancer, N = 2; rectal
carcinoma, N = 1; and melanoma, N = 1). Preoperative
VAS scores were 10 out of 10 in all 5 patients. Table 1
presents a summary of patient VAS scores over time.
Case Presentations
Patient 1
Patient 1 was a 72-year-old woman with renal cell carci-
noma. The patient had disseminated bony metastases
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and presented with refractory pain in the pelvis, sacrum,
and buttocks, with an intial VAS pain score of 10. She
underwent IT pump placement with the catheter tip at the
superior endplate of L1, with a dosage of morphine 2 mg/
day and bupivacaine 0.5% at 4 mg/day. She initially
responded with a VAS score of 0, and IT neuromodulation
continued to control her sacral and right hip pain until a
pathological fracture of the right iliac bone and right ante-
rior acetabulum considerably increased her pain. IT medi-
cations were titrated, with increases of morphine to 5 mg/
day and bupivacaine to 10 mg/day. She subsequently
rated her pain at VAS 9. As the pain was unilateral on the
right, a left PRFC was performed, with complete pain relief
(VAS 0). Analgesia was maintained at VAS ≤ 1 until she
expired 3 months after the PRFC procedure.
Patient 2
Patient 2 was a 51-year-old male with rectal cancer and
metastatic disease to the thoracic spine and pleura,
causing refractory upper chest wall pain at approximately
T6-8, with VAS pain score of 10. The patient underwent IT
pump placement with a catheter tip at T8, and he received
hydromorphone 2.65 mg/day and bupivacaine 5.3 mg/
day. His pain initially improved to a 9, and IT medication
doses were subsequently increased to 5.49 and
13.74 mg/day, respectively, and ziconotide 3.29 mg/day
was added. Despite the increased dosage, the patient’s
pain remained at VAS 9. To improve his pain control, a
right-sided PRFC was performed. The patient experi-
enced an immediate decrease in chest pain, no longer
required IT boluses, and was weaned off all oral pain
medications. He continued to receive hydromorphone
0.5 mg/day, bupivacaine 1.25 mg/day, and ziconitide
0.4 mcg/day via the IT pump. Pain at three month
follow-up was rated as VAS 4. The patient was then
transferred into hospice care.
Patient 3
Patient 3 was a 16-year-old female with a history of mela-
noma and metastases to the small intestine. Due to intrac-
table abdominal pain at VAS 10, she was admitted to the
intensive care unit and a dexmedetomidine infusion was
administered along with maximal opioid therapy. The pain
persisted. A percutaneous MM (see [32] for detailed tech-
nical description) was performed was performed at the T5
level. The dexmedetomidine infusion was halted and the
patient reported VAS 3 pain. Two months following the
MM procedure, her pain returned to VAS 9. The patient
then underwent IT pump placement with a catheter tip at
T10. IT doses initially were hydromorphone 1.2 mg/day
and bupivacaine 1.2 mg/day. This was increased to
hydromorphone 2.6 mg/day and bupivacaine 2.6 mg/day.
Following IT pump placement and titration, the patient
reported VAS 7 pain at 3-month follow-up.
Patient 4
Patient 4 was a 64-year-old male with non-small cell lung
cancer who had severe right-sided chest pain secondary
to chest wall metastases. After chemoradiation and
maximal systemic opioids, his pain remained at VAS 10.
Initially, an IT pump was placed with the catheter tip at T6.
Following the procedure, the patient was started on mor-
phine and bupivacaine. Pain remained at VAS 9-10, and
hydromorphone was attempted instead. Clonidine was
also added. Analgesic doses were increased to the point
of paraparesis and urinary retention, up to a maximum
dose of hydromorphone 3,425 mcg/day and bupivacaine
20.549 mg/day. Therefore, a left PRFC was performed
resulting in immediate and complete resolution of the right
chest wall pain. IT dosage was decreased by 75%. Later,
following development of new, opiate-responsive left-
sided pain due to a small metastatic lesion, IT dosage was
increased. His pain remained at VAS ≤ 1 until his death 9
months after PRFC.
Patient 5
Patient 5 was a 71-year-old male who presented with
chest wall pain that extended to the top of the shoulder
and lower neck, mechanical low back pain, and a left
apical pulmonary mass. He was diagnosed with non-small
cell lung cancer and was found to have metastatic sacral
lesions producing low back pain. Despite radiotherapy
and escalating opioid dosage, he continued to have VAS
10 pain that inhibited weight-bearing and upright stand-
ing. An IT pump was implanted several segments above
his pain, with the catheter tip at C4, and he received
Table 1 Progression of VAS scores in a multicenter series of cancer-pain patients treated with IT and
ablative therapies
Patient
No.
Age (yrs),
Sex Diagnosis
Initial VAS
Score
First
Procedure
Pre-Procedure
VAS Score
Second
Procedure
Postoperative
VAS Score
Long-Term VAS
Score (mos)
1 72, F Renal 10 IT pump 9 Cordotomy 0 1 (3)
2 51, M Rectal 10 IT pump 9 Cordotomy 4 4 (3)
3 16, F Melanoma 10 Myelotomy 9 IT pump 7 7 (3)
4 64, M NSCLC 10 IT pump 9–10 Cordotomy 0 1 (9)
5 71, M NSCLC 10 IT pump 10 Myelotomy 3–4 4 (6)
IT = intrathecal; NSCLC = non-small cell lung cancer; VAS = visual analog scale.
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hydromorphone and bupivacaine, which completely alle-
viated his chest wall pain. Doses were increased,
however, he continued to have intractable midline sacral
pain, and therefore underwent open myelotomy at T9-10,
resulting in 70–80% relief of pain (VAS 3–4), allowing
sitting, standing, and ambulating. He continued to expe-
rience stable pain relief with improved quality of life until his
death 6 months later.
Discussion
Cancer pain arises from various sources and is mediated
by diverse mechanisms. The direct effect of tumor inva-
sion into bones, soft tissues, or obstruction of hollow
viscera accounts for 75% of all cancer pain [5]. Chemo-
therapy and radiation may also result in painful fibrosis or
myopathies, and procedural pain from surgical resection,
venipuncture, or bone marrow aspirations is also
common causes [35,36]. Incidence and severity of
cancer pain has been correlated with degraded func-
tional ability and diminished quality of life. In a 10-year
prospective study of 2,266 cancer patients, Zech et al.
[37] reported that 12% of patients reported “severe,”
“very severe,” or “maximal” pain greater than 30% of the
time, despite medical management. Cleeland et al. [38]
reported that inadequate pain control resulted in interfer-
ence with work, relationships, enjoyment of life, and
other activities of daily living. While cancer patients
contend with the many medical issues surrounding their
primary diagnosis, uncontrolled pain significantly limits
their overall quality of life. In 1986, the World Health
Organization (WHO) published a now well-established
guideline for the treatment of cancer pain [39].The WHO
recommends a 3-step ladder approach, with treatment
progressing from non-opioid analgesics to mild oral
opioids, then to strong oral opioids. The stated goal of
the WHO guidelines has been to provide relief from pain
“to the patient’s satisfaction, so that [they] may function
effectively and eventually die free from pain” [39].
However, due to various reasons, it is estimated that
only half of cancer patients are treated according to the
guidelines, leaving 50% of cancer patients undertreated
[20,40]. In addition to undertreated patients, 10% of
cancer patients will continue to have pain even with
optimal medical therapy [41]. With the number of new
cancer diagnoses per year estimated to approach 15 to
17 million worldwide in 2020, pain in this medically
intractable population represents a significant public
health concern [42]. Even by the most optimistic esti-
mates, assuming a low incidence of terminal cancer pain
(60%), full guideline implementation, and 90% treat-
ment success, almost 1 million patients worldwide are
expected to suffer from severe pain that fails to respond
to oral medications [43].
For these patients with moderate-to-severe and medi-
cally intractable cancer pain, both IT-targeted drug deliv-
ery and neurosurgical ablation are treatment strategies
with demonstrated safety and efficacy [13,44]. Many
other procedures are in use, with varying success.
Among these are peripheral nerve or plexus anesthetic
blockade, chemical neurolysis, and spinal cord stimula-
tion (SCS). Each of these has its own risk-benefit profile,
and have been variable successful. Recurrence of pain
occurs frequently, and is a significant factor in determin-
ing surgical candidates for these procedures. Serial
attempts have few proponents, as this increases the rate
of complication from damage to surrounding tissues,
neurologic deficit, and development of new pain.
However, they as relatively straightforward and have low
associated morbidity, and therefore, continue to be
useful adjuncts and worthy of trying before moving to
more permanent approaches [45].
Recently, comprehensive consensus guidelines have
emerged for the treatment of cancer pain with IT
neuromodulation [44]. In malignancy, it is generally more
commonly performed than SCS due to the presence of
well-designed randomized control trials showing its
effectiveness when used in conjunction with maximal
medical management [18]. In a randomized controlled
comparison of the two, both SCS and IT therapy pro-
vided pain reduction, though there was a trend toward
greater pain relief with IT therapy [46]. Administration
of IT opioids is the most extensively studied
neuromodulatory intervention for chronic pain, first
described in 1979 by Wang et al. [15], who found a
potent analgesic effect with serial bolus dosing adminis-
tered to the subarachnoid space. In a randomized con-
trolled trial, Smith et al. [18] reported that 84.5% of
patients experienced successful pain relief with the use
of IT pumps, in comparison to 70.8% of patients receiv-
ing comprehensive medical management (P = 0.05).
Additionally, rates of cognitive and systemic toxicities
were far lower among patients receiving IT therapy. IT
therapy is currently indicated for use in patients with
intractable nociceptive and neuropathic pain who
respond well to oral opioids, but despite increased and
optimized doses, continue to have pain [44]. In addition,
it is indicated for use in patients for whom oral therapy is
associated with intolerable systemic side effects, such as
nausea, pruritus, urinary retention, or respiratory depres-
sion. Currently, the only FDA-approved analgesic medi-
cations for IT pumps are morphine and ziconitide
However, according to consensus guidelines pub-
lished in 2007, monotherapy with either morphine,
hydromorphone, or ziconitide are acceptable first-line
treatments [44]. Failure to adequately control pain with
these medications warrants use of second-line therapies,
which includes replacement of a first-line medication with
fentanyl, or addition of either bupivacaine or clonidine to
ziconitide. Third-line therapy warrants use of ziconitide
with a second-line therapy, or clonidine monotherapy.
Fourth-line treatments include addition of sufentanil,
ropivicaine, buprenorphine, midazolam, meperidine,
or ketorolac, octreotide, gabapentin, or investigational
medications [44].
Though these guidelines note that third-line pharmaco-
logical therapies and beyond have limited clinical efficacy
data, no mention is made of the addition of neuroablative
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therapies for synergistic pain control. Although IT targeted
drug delivery and neurosurgical ablation are well-
described and effective options, poor response to these
procedures and/or recurrence of pain are well-recognized
possibilities. Recommendations on how best to proceed
after failure of one of these treatments are unavailable to
treating physicians [33,47]. While it may seem that failure
of an invasive procedure precludes further surgical inter-
vention, our results illustrate a variety of patient conditions
and presentations in which a combination of IT therapy
and ablation was used effectively and safely. Based on our
results, earlier intervention with these may provide imme-
diate and durable pain control, decreasing the amount of
time necessary for medication titration. This is particularly
well-illustrated in patients 1, 2, 4, and 5, who initially had
an IT pump placed and underwent medication titration
with additional second- and third-line therapies, but con-
tinued to have refractory pain. Rather than continue down
the avenue of medication trial-and-error, neuroablation
resulted in excellent pain relief, decreasing the need for IT
analgesia.
Before considering the initial surgery a treatment failure,
physicians should adopt a methodical approach to
ensuring optimal therapy is being delivered. Develop-
ment of pain in a new area should prompt evaluation for
new metastases. As illustrated in Patient 4, some lesions
may be opioid-unresponsive or persist due to opioid tol-
erance, while others in the same patient respond well.
Though the pathophysiologic mechanism of this dispa-
rate response is not understood, we achieved good
control of pain by progressing along the same algorithm,
beginning with the most conservative approach of oral/
epidural medication titration. If a pump is implanted, it is
important to interrogate it in the initial evaluation. X-rays
should be obtained to ensure that failure is not due to
catheter migration, breakage, or kinks, and occasionally
nuclear medicine studies are indicated to evaluate for
obstruction. The catheter tip is generally optimally placed
several segments above the level of pain, though in the
authors’ experience with IT pumps and bolus IT trials,
pain relief is achieved even when the tip is at or a couple
of segments below the site of pain. The ablative proce-
dures are most strongly indicated for pain from malig-
nancy, as pain recurrence is a significant concern,
though long-term relief has been reported for up to 40
years with cordotomy [48]. For cordotomy, return
of pain is seen in about 50–60% of patients at one year
[34], and in MM, return of pain was seen in 30% at 6
months [14].
In addition, there are no clear-cut guidelines for which
initial therapy is best, and some outcomes may be
unpredictable and surprising, as in our third and fifth
patients. In the third case, the patient seemed an excel-
lent candidate for initial MM due to the inadequate
response to oral and IV analgesics and well-localized
midline abdominal pain. However, failing this, subse-
quent IT implantation provided much more relief,
begging the question of whether an IT pump would have
been a better first choice. In retrospect, this is a valid
question, but would not have been predicted based on
her previous clinical response. Though this case may
present clinical frustration at the difficulty in patient selec-
tion, it highlights the need for evaluation by specialists
familiar with the many available modalities. In the case of
the fifth patient, it is worthy to wonder if both treatments
should have been done simultaneously, as his pain was
Figure 1 Proposed treatment algorithm for the approach to management of cancer patients with medically
refractory pain.
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widely disparate. IT pump was initially placed as the
most conservative approach, with the hope of covering
the whole extent of his pain. However, it was not until
some time later that this was deemed a failure. As so
many patients respond well to IT therapy, it is usual
practice to trial this and ensure it is optimized before
subjecting patients to a second procedure.
In our series, no complications from neurosurgical ablation
or IT pharmacotherapy were observed. Operative time,
hospital length of stay, and postoperative courses were as
expected for these operations. Furthermore, whether
ablation preceded neuromodulation or vice-versa, all
patients experienced some benefit. Based on our results
and the previously described WHO approach, we recom-
mend consideration of an approach to persistent refrac-
tory cancer pain as illustrated in Figure 1, though
consideration should also be given to SCS, neurectomy,
or nerve blockade in appropriately selected individuals.
We fully acknowledge that our small, retrospective series
provides only a first step to develop a broader consen-
sus and evidence-based paradigm incorporating medical
management, IT neuromodulation, and neurosurgical
ablation. Among three institutions, five patients under-
went both neuromodulatory (IT pump placement) and
neuroablative (myelotomy or cordotomy) for cancer pain
control. While this may be due to the rarity of the occur-
rence of persistent pain in the setting of an initial proce-
dure and successful medical management thereafter, it
may also be due to a hesitancy to refer patients for sec-
ondary procedures. A much larger cohort of cancer pain
patients are needed to fully understand the safety and
efficacy of this treatment algorithm. However, in order to
provide treatment options for this group of patients, we
advocate for a persistent approach, combining medical,
modulatory, and ablative modalities.
Conclusions
Medically intractable cancer pain presents an enormous
challenge, robbing cancer patients of quality of life in the
terminal stages of their disease. In an effort to expand
upon the current guidelines for management of these
patients, we have presented a series of patients in whom
a combination of neurosurgical modulation and ablation
were both safe and efficacious.
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